To order this 350+ page report, which features 130+ figures and 190+ tables, please visit this link
The USD 9.2 billion (by 2030) financial opportunity within the RNAi therapeutics market has been analyzed across the following segments:
- Key therapeutic areas
- Oncological disorders
- Infectious diseases
- Genetic disorders
- Ophthalmic disorders
- Hepatic disorders
- Respiratory disorders
- Type of RNAi molecule
- siRNA
- miRNA
- shRNA
- sshRNA
- DNA
- Route of administration
- Subcutaneous
- Intravenous
- Intradermal
- Intratumoral
- Intravitreal
- Oral
- Intramuscular
- Key geographical regions
- North America
- Europe
- Asia Pacific and the Rest of the World
- Leading Players
The RNAi Therapeutics Market (2nd Edition), 2019-2030” report features the following companies, which we identified to be key players in this domain:
- Quark Pharmaceuticals
- Alnylam Pharmaceuticals
- Dicerna Pharmaceuticals
- Souzhou Ribo Life Sciences
- Olix Pharmaceuticals
- Sirnaomics
- Ariz Precision Medicine
- Arrowhead Pharmaceuticals
- Gradalis
- Benitec Biopharma
Table of Contents
1. PREFACE
2. EXECUTIVE SUMMARY
3. INTRODUCTION
4. COMPETITIVE LANDSCAPE
5. COMPANY COMPETITIVENESS ANALYSIS
6. LATE STAGE RNAi THERAPEUTICS
7. TECHNOLOGY PLATFORMS AND DELIVERY SYSTEMS
8. KEY THERAPEUTIC INDICATIONS
9. CLINICAL TRIAL ANALYSIS
10. PATENT ANALYSIS
11. RECENT PARTNERSHIPS
12. FUNDING AND INVESTMENT ANALYSIS
13. PROMOTIONAL ANALYSIS
14. MARKET SIZING AND OPPORTUNITY ANALYSIS
15. RNAi IN DIAGNOSTICS
16. SERVICE PROVIDERS FOR RNAi THERAPEUTICS
17. SWOT ANALYSIS
18. CONCLUSION
19. INTERVIEW TRANSCRIPT(S)
20. APPENDIX 1: TABULATED DATA
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/rnai-therapeutics-market-2nd-edition-2019-2030/278.html
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
